Concert Pharmaceuticals Inc

Concert Pharmaceuticals — Investor Presentation (May 2022)

17 slides from Concert Pharmaceuticals's investor presentation, May 23, 2022

  1. Slide 1: Creating New Possibilities for Patients to Live Their Lives

    Exhibit 99.1 Creating New Possibilities for Patients to Live Their Lives May 2022 © 2022 Concert Pharmaceuticals, Inc. All Rights Reserved.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Any statements in this presentation about our future expectations, plans and prospects, including, among others, statements about our expectations regarding the development of CTP-543, the potential for CTP-543 to be a best-in-class treatment for the treatment of alopecia

  3. Slide 3: CoNCERT: Creating New Opportunities in Dermatology

    CoNCERT: Creating New Opportunities in Dermatology Late-stage, Cash into Developing Successfully small molecules patient-centric, out-licensed fourth for autoimmune clinical multiple quarter of company 2022 dermatology candidates • Creating novel, • Successfully completed • Out-license of non-core •

  4. Slide 4: Late-Stage Clinical Program and Strategic Value Creation Anticipated

    Late-Stage Clinical Program and Strategic Value Creation Anticipated Phase 1 Phase 2 Phase 3 Milestones Ownership THRIVE-AA2 THRIVE-AA1 Positive Topline Results Reported Wholly Owned By: topline data expected Q3 2022 Alopecia CTP-543 THRIVE-AA2 Fully Enrolled Areata Deuruxolitinib NDA submission NDA

  5. Slide 5: CTP-543: Compelling Opportunity for Alopecia Areata

    CTP-543: Compelling Opportunity for Alopecia Areata Large Market/No FDA-Approved Tx Strong Patent Protection • Serious autoimmune disorder with • Orange Book-eligible patent significant unmet patient need protection into 2037 • CTP-543 has Breakthrough Therapy • Patent portfolio expansion ongoing de

  6. Slide 6: Alopecia Areata: A Devastating Autoimmune Disease

    Alopecia Areata: A Devasting Autoimmune Disease Significant Burden No FDA-approved Common Disorder of Disease Treatment Options • Disease profoundly • Strong patient advocacy • Up to approximately 1.5 impacts patients million patients affected • FDA PFDDI meeting held with alopecia areata in • Patie

  7. Slide 7: CTP-543 Phase 2: Meaningful Hair Regrowth Observed

    CTP-543 Phase 2: Meaningful Hair Regrowth Observed Phase 2 - CTP-543 Response Over Treatment Period: 12 mg BID 7

  8. Slide 8: THRIVE-AA1 Study Achieves Primary Endpoint: Both Doses Highly Statistically Different From Placebo

    THRIVE-AA1 Study Achieves Primary Endpoint: Both Doses Highly Statistically Different From Placebo • Randomized 706 adult patients with moderate to severe alopecia areata in CTP-543 Phase 3 Results a double-blind, randomized, placebo- Primary Endpoint: Patients Achieving Absolute SALT Score ≤20 at W

  9. Slide 9: CTP-543: Statistically Significant Differences from Placebo of Hair Regrowth as Early as Eight Weeks

    CTP-543: Statistically Significant Differences from Placebo of Hair Regrowth as Early as Eight Weeks THRIVE-AA1 Key Secondary Endpoint: Patients Achieving Absolute SALT Score ≤20 by Weeks on Treatment 60 50 ***** 42% ***** 40 ***** ***** 30% 30 ***** ***** 20 ***** ***** 10 **** **** 1% 0 Week 8 Wee

  10. Slide 10: CTP-543: Highly Statistically Significant Differences vs Placebo in Patient Satisfaction at Week 24

    CTP-543: Highly Statistically Significant Differences vs Placebo in Patient Satisfaction at Week 24 THRIVE-AA1 Key Secondary Endpoint: Satisfaction of Hair Patient Reported Outcome (SPRO) Responders at Week 24 60 ***** 53% 50 ***** 42% 40 30 20 10 5% 0 Placebo 8 mg BID 12 mg BID n= 140 n= 351 n= 215

  11. Slide 11: THRIVE-AA1: Favorable Safety/Tolerability Profile

    THRIVE-AA1: Favorable Safety/Tolerability Profile • CTP-543 treatment was generally well tolerated ‒ >90% of eligible patients elected to roll into open label, long-term extension study • 9 patients reported SAEs: placebo (4), 8 mg twice-daily (4) and 12 mg twice-daily (1) ‒ Only 1 patient (8 mg) re

  12. Slide 12: CTP-543: Potential Best-in-Class Treatment in Alopecia Areata

    CTP-543: Potential Best-in-Class Treatment in Alopecia Areata For both CTP-543 doses: Baseline Week 12 Week 24 ✓ Primary endpoint achieved: significant scalp regrowth at 24 weeks ✓ Early onset of effect: significant differences as early as 8 weeks and maintained throughout study ✓ Patient satisfacti

  13. Slide 13: CTP-543 Phase 3 THRIVE-AA2: Topline Data Expected Q3 2022

    CTP-543 Phase 3 THRIVE-AA2: Topline Data Expected Q3 2022 THRIVE-AA program designed to support NDA filing in 1H 2023 • Double-blind, randomized, placebo-controlled trial • In adults with moderate to severe alopecia areata THRIVE-AA2 • Enrollment: 517 patients age 18-65 years with ≥ 50% hair loss De

  14. Slide 14: CTP-543 for Alopecia Areata: Pre-Commercial Planning

    CTP-543 for Alopecia Areata: Pre-Commercial Planning Large, chronic A ready segment Clear market disease now of motivated opportunity recognized as patients with with significant autoimmune high burden of growth disorder disease potential • CTP-543 has highly competitive profile based on Phase 3 res

  15. Slide 15: CTP-543: Compelling Opportunity for Alopecia Areata

    CTP-543: Compelling Opportunity for Alopecia Areata Large Market/No FDA-Approved Tx Strong Patent Protection • Serious autoimmune disorder with • Orange Book-eligible patent significant unmet patient need protection into 2037 • CTP-543 has Breakthrough Therapy • Patent portfolio expansion ongoing de

  16. Slide 16: Financial Position and Milestones

    Financial Position and Milestones • Cash, cash equivalents and investments: $109M Financial Position • Potential to receive additional $103.1M under (Q1 2022) financing arrangement* ✓ Successful THRIVE-AA1 Phase 3 trial topline results reported Q2 2022 Clinical Milestones • THRIVE-AA2 Phase 3 trial

  17. Slide 17: Contact: www.concertpharma.com

    NASDAQ: CNCE www.concertpharma.com @ConcertPharma For additional information contact: Justine Koenigsberg [email protected] © 2022 Concert Pharmaceuticals, Inc. All Rights Reserved.

Concert Pharmaceuticals — Investor Presentation (May 2022) on 6ix